| (R)-FTY 720P |
|
|
|
|
|
|
|
|
|
|
| (R)-SLB1122168 free base |
|
|
|
|
|
|
|
|
|
|
| (R)-VPC44116 |
|
|
|
|
|
|
|
|
|
|
| (S)-FTY-720 Vinylphosphonate |
|
|
|
|
|
|
|
|
|
|
| (S)-FTY720-phosphonate |
|
|
|
|
|
|
|
|
|
99.91% |
| (S)-PF-462991 |
|
|
|
|
|
|
|
|
|
|
| 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA |
|
|
|
|
|
|
|
|
|
|
| 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA sodium |
|
|
|
|
|
|
|
|
|
|
| 1-Hexadecyl lysophosphatidic acid sodium |
|
|
|
|
|
|
|
|
|
|
| 1-Octadecyl lysophosphatidic acid |
|
|
|
|
|
|
|
|
|
95% |
| 1-Oleoyl lysophosphatidic acid |
|
|
|
|
|
|
|
|
|
99.90% |
| 1-Oleoyl lysophosphatidic acid sodium |
|
|
|
|
|
|
|
|
|
|
| 1-Oleoyl lysophosphatidic acid sodium |
|
|
|
|
|
|
|
|
|
99.96% |
| 2-Acetyl-4-tetrahydroxybutyl imidazole |
|
|
|
|
|
|
|
|
|
98.06% |
| 2-Acetyl-4-tetrahydroxybutyl imidazole-13C6 |
|
|
|
|
|
|
|
|
|
|
| 2ccPA sodium |
|
|
|
|
|
|
|
|
|
|
| A-971432 |
|
|
|
|
|
|
|
|
|
99.31% |
| A6770 |
|
|
|
|
|
|
|
|
|
98.23% |
| AB1 |
|
|
|
|
|
|
|
|
|
|
| ACT-1016-0707 |
|
|
|
|
|
|
|
|
|
98.28% |
| ACT-209905 |
|
|
|
|
|
|
|
|
|
|
| AM095 |
|
|
|
|
|
|
|
|
|
99.72% |
| AM095 free acid |
|
|
|
|
|
|
|
|
|
99.02% |
| AM966 |
|
|
|
|
|
|
|
|
|
99.86% |
| AMG 369 |
|
|
|
|
|
|
|
|
|
|
| Amiselimod |
|
|
|
|
|
|
|
|
|
|
| Amiselimod hydrochloride |
|
|
|
|
|
|
|
|
|
98.86% |
| Anti-LPA/Lysophosphatidic acid Antibody (504B3) |
|
|
|
|
|
|
|
|
|
|
| AS2717638 |
|
|
|
|
|
|
|
|
|
99.85% |
| ASP-4058 |
|
|
|
|
|
|
|
|
|
99.54% |
| ASP-4058 hydrochloride |
|
|
|
|
|
|
|
|
|
99.71% |
| ASP1126 |
|
|
|
|
|
|
|
|
|
|
| ASP6432 |
|
|
|
|
|
|
|
|
|
99.92% |
| ATX inhibitor 27 |
|
|
|
|
|
|
|
|
|
|
| Autotaxin-IN-6 |
|
|
|
|
|
|
|
|
|
99.88% |
| Autotaxin-IN-8 |
|
|
|
|
|
|
|
|
|
|
| AUY 954 hydrochloride |
|
|
|
|
|
|
|
|
|
|
| AUY954 |
|
|
|
|
|
|
|
|
|
|
| AzoLPA ammonium |
|
|
|
|
|
|
|
|
|
|
| BMS-520 |
|
|
|
|
|
|
|
|
|
|
| BMS-960 |
|
|
|
|
|
|
|
|
|
|
| BMS-960 free base |
|
|
|
|
|
|
|
|
|
|
| BMS-986020 |
|
|
|
|
|
|
|
|
|
99.91% |
| BMS-986020 sodium |
|
|
|
|
|
|
|
|
|
99.88% |
| BMS-986104 |
|
|
|
|
|
|
|
|
|
|
| BMS-986104 hydrochloride |
|
|
|
|
|
|
|
|
|
|
| BMS-986278 |
|
|
|
|
|
|
|
|
|
99.93% |
| BMT-136088 |
|
|
|
|
|
|
|
|
|
|
| BrP-LPA |
|
|
|
|
|
|
|
|
|
|
| BrP-LPA sodium |
|
|
|
|
|
|
|
|
|
|
| C16-Sphingosine-1-phosphate |
|
|
|
|
|
|
|
|
|
99.9% |
| CAY10444 |
|
|
|
|
|
|
|
|
|
98.0% |
| CAY10734 |
|
|
|
|
|
|
|
|
|
|
| Cenerimod |
|
|
|
|
|
|
|
|
|
99.43% |
| Ceralifimod |
|
|
|
|
|
|
|
|
|
99.29% |
| Ceranib-2 |
|
|
|
|
|
|
|
|
|
98.92% |
| CRT0273750 |
|
|
|
|
|
|
|
|
|
98.81% |
| CS-0777 |
|
|
|
|
|
|
|
|
|
|
| CS-0777-P |
|
|
|
|
|
|
|
|
|
|
| CS-2100 |
|
|
|
|
|
|
|
|
|
99.12% |
| CS1P1 |
|
|
|
|
|
|
|
|
|
|
| Cudetaxestat |
|
|
|
|
|
|
|
|
|
98.32% |
| CYM-5478 |
|
|
|
|
|
|
|
|
|
99.44% |
| CYM-5482 |
|
|
|
|
|
|
|
|
|
98.29% |
| CYM-5520 |
|
|
|
|
|
|
|
|
|
98.61% |
| CYM-5541 |
|
|
|
|
|
|
|
|
|
99.98% |
| CYM50179 |
|
|
|
|
|
|
|
|
|
96.06% |
| CYM50260 |
|
|
|
|
|
|
|
|
|
98.94% |
| CYM50308 |
|
|
|
|
|
|
|
|
|
98.0% |
| CYM50358 |
|
|
|
|
|
|
|
|
|
98.33% |
| CYM50358 hydrochloride |
|
|
|
|
|
|
|
|
|
|
| CYM50374 |
|
|
|
|
|
|
|
|
|
|
| CYM5181 |
|
|
|
|
|
|
|
|
|
|
| CYM5442 |
|
|
|
|
|
|
|
|
|
98.83% |
| CYM5442 hydrochloride |
|
|
|
|
|
|
|
|
|
|
| Decyl phosphate |
|
|
|
|
|
|
|
|
|
|
| Etrasimod |
|
|
|
|
|
|
|
|
|
99.91% |
| Etrasimod arginine |
|
|
|
|
|
|
|
|
|
99.86% |
| Etrasimod-d9 |
|
|
|
|
|
|
|
|
|
|
| Ex26 |
|
|
|
|
|
|
|
|
|
99% |
| Fingolimod phosphate |
|
|
|
|
|
|
|
|
|
99.18% |
| Fingolimod phosphate-d4 |
|
|
|
|
|
|
|
|
|
|
| FTY720 (S)-Phosphate |
|
|
|
|
|
|
|
|
|
99.57% |
| Ginkgolic acid 2-phosphate |
|
|
|
|
|
|
|
|
|
|
| GLPG2938 |
|
|
|
|
|
|
|
|
|
99.94% |
| Glycocholic acid |
|
|
|
|
|
|
|
|
|
99.90% |
| Glycocholic acid hydrate |
|
|
|
|
|
|
|
|
|
99.85% |
| Glycocholic acid sodium |
|
|
|
|
|
|
|
|
|
97.0% |
| Glycocholic acid-13C2,d4N |
|
|
|
|
|
|
|
|
|
|
| Glycocholic acid-d4 |
|
|
|
|
|
|
|
|
|
99.92% |
| GRI977143 |
|
|
|
|
|
|
|
|
|
99.29% |
| GS-2278 |
|
|
|
|
|
|
|
|
|
98.70% |
| GSK 1842799 TFA |
|
|
|
|
|
|
|
|
|
|
| GSK-2262167 sodium |
|
|
|
|
|
|
|
|
|
|
| GSK1842799 |
|
|
|
|
|
|
|
|
|
|
| GSK2018682 |
|
|
|
|
|
|
|
|
|
98.02% |
| GSK2018682 hydrochloride |
|
|
|
|
|
|
|
|
|
|
| GSK2263167 |
|
|
|
|
|
|
|
|
|
|
| GSK3178022 |
|
|
|
|
|
|
|
|
|
|
| H2L 5765834 |
|
|
|
|
|
|
|
|
|
98.66% |
| H2L5186303 |
|
|
|
|
|
|
|
|
|
98.50% |
| H2L5186303 (Standard) |
|
|
|
|
|
|
|
|
|
|
| HL001 |
|
|
|
|
|
|
|
|
|
98.90% |
| Icanbelimod |
|
|
|
|
|
|
|
|
|
99.90% |
| IMMH001 |
|
|
|
|
|
|
|
|
|
98.10% |
| JTE-013 |
|
|
|
|
|
|
|
|
|
99.57% |
| Ki16198 |
|
|
|
|
|
|
|
|
|
98.17% |
| Ki16425 |
|
|
|
|
|
|
|
|
|
99.14% |
| KRO-105714 |
|
|
|
|
|
|
|
|
|
|
| KRP-203 monophosphate |
|
|
|
|
|
|
|
|
|
|
| KSI-6666 |
|
|
|
|
|
|
|
|
|
96.15% |
| L-NASPA |
|
|
|
|
|
|
|
|
|
|
| L-NASPA ammonium |
|
|
|
|
|
|
|
|
|
|
| L-threo Lysosphingomyelin (d18:1) |
|
|
|
|
|
|
|
|
|
98.0% |
| Lp(a)-IN-8 |
|
|
|
|
|
|
|
|
|
|
| LPA receptor antagonist-1 |
|
|
|
|
|
|
|
|
|
|
| LPA1 receptor antagonist 1 |
|
|
|
|
|
|
|
|
|
99.13% |
| LPA1 receptor antagonist-7 |
|
|
|
|
|
|
|
|
|
|
| LPA2 antagonist 1 |
|
|
|
|
|
|
|
|
|
98.63% |
| LPA2 antagonist 2 |
|
|
|
|
|
|
|
|
|
95.0% |
| LPA2 antagonist 5 |
|
|
|
|
|
|
|
|
|
|
| LPA2 antagonist 6 |
|
|
|
|
|
|
|
|
|
|
| LPA5 antagonist 2 |
|
|
|
|
|
|
|
|
|
99.62% |
| LPA5 antagonist 3 |
|
|
|
|
|
|
|
|
|
|
| LPAR1 antagonist 1 |
|
|
|
|
|
|
|
|
|
98.85% |
| LPAR1 antagonist 2 |
|
|
|
|
|
|
|
|
|
|
| Lpathomab |
|
|
|
|
|
|
|
|
|
|
| LX2931 |
|
|
|
|
|
|
|
|
|
98.88% |
| LX2932 |
|
|
|
|
|
|
|
|
|
|
| MK-571 |
|
|
|
|
|
|
|
|
|
98.85% |
| MK-571 sodium |
|
|
|
|
|
|
|
|
|
99.75% |
| Mocravimod |
|
|
|
|
|
|
|
|
|
98.39% |
| Mocravimod hydrochloride |
|
|
|
|
|
|
|
|
|
99.99% |
| Myristoyl pentapeptide-17 acetate |
|
|
|
|
|
|
|
|
|
|
| N-PTyrosine PA ammonium |
|
|
|
|
|
|
|
|
|
|
| NAEPA |
|
|
|
|
|
|
|
|
|
98.06% |
| NIBR0213 |
|
|
|
|
|
|
|
|
|
98.91% |
| NSC12404 |
|
|
|
|
|
|
|
|
|
|
| Obicetrapib |
|
|
|
|
|
|
|
|
|
99.93% |
| Obicetrapib potassium |
|
|
|
|
|
|
|
|
|
|
| Obicetrapib sodium |
|
|
|
|
|
|
|
|
|
|
| ONO-0300302 |
|
|
|
|
|
|
|
|
|
98.02% |
| ONO-0740556 |
|
|
|
|
|
|
|
|
|
99.78% |
| ONO-7300243 |
|
|
|
|
|
|
|
|
|
98.11% |
| ONO-9780307 |
|
|
|
|
|
|
|
|
|
99.94% |
| ONO-9910539 |
|
|
|
|
|
|
|
|
|
|
| Ozanimod hydrochloride |
|
|
|
|
|
|
|
|
|
98.10% |
| Palmitoyl 3-carbacyclic phosphatidic acid |
|
|
|
|
|
|
|
|
|
99.9% |
| PF-462991 |
|
|
|
|
|
|
|
|
|
|
| PF-543 |
|
|
|
|
|
|
|
|
|
99.85% |
| PF-543 Citrate |
|
|
|
|
|
|
|
|
|
99.47% |
| PF-543 hydrochloride |
|
|
|
|
|
|
|
|
|
|
| Ponesimod |
|
|
|
|
|
|
|
|
|
99.78% |
| Ponesimod-d4 |
|
|
|
|
|
|
|
|
|
|
| pro-FTY |
|
|
|
|
|
|
|
|
|
|
| Radioprotectin-1 |
|
|
|
|
|
|
|
|
|
99.49% |
| RBM10-8 |
|
|
|
|
|
|
|
|
|
|
| RP-001 |
|
|
|
|
|
|
|
|
|
|
| RP-001 hydrochloride |
|
|
|
|
|
|
|
|
|
98.8% |
| RP-1859 |
|
|
|
|
|
|
|
|
|
|
| RP101075 |
|
|
|
|
|
|
|
|
|
99.19% |
| RP101442 |
|
|
|
|
|
|
|
|
|
|
| RP101988 |
|
|
|
|
|
|
|
|
|
98.80% |
| S1p receptor agonist 2 |
|
|
|
|
|
|
|
|
|
|
| S1P1 agonist 1 |
|
|
|
|
|
|
|
|
|
99.92% |
| S1P1 agonist 4 |
|
|
|
|
|
|
|
|
|
|
| S1P1 agonist 5 |
|
|
|
|
|
|
|
|
|
|
| S1P1 agonist 6 |
|
|
|
|
|
|
|
|
|
|
| S1P1 agonist 7 |
|
|
|
|
|
|
|
|
|
|
| S1P1 agonist III |
|
|
|
|
|
|
|
|
|
99.64% |
| S1P2 antagonist 1 |
|
|
|
|
|
|
|
|
|
|
| S1P5 receptor agonist-1 |
|
|
|
|
|
|
|
|
|
|
| S1P5 receptor antagonist 1 |
|
|
|
|
|
|
|
|
|
|
| S1PL-IN-
2 |
|
|
|
|
|
|
|
|
|
|
| S1PL-IN-1 |
|
|
|
|
|
|
|
|
|
99.9% |
| S1PR1 agonist 1 |
|
|
|
|
|
|
|
|
|
|
| S1PR1 agonist 2 |
|
|
|
|
|
|
|
|
|
|
| S1PR1 agonist 3 |
|
|
|
|
|
|
|
|
|
|
| S1PR1 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| S1PR1 ligand 1 |
|
|
|
|
|
|
|
|
|
|
| S1PR1 modulator 1 |
|
|
|
|
|
|
|
|
|
99.52% |
| S1pr1 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| S1pr1 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| S1PR1-MO-1 |
|
|
|
|
|
|
|
|
|
|
| S1PR1/S1PR5 agonist-1 |
|
|
|
|
|
|
|
|
|
|
| S1PR2 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| S1pr2 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| S1pr2 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| S1PR3 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| S1pr3 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| S1PR4 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| S1pr4 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| S1PR5 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| S1pr5 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| S1pr5 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| S1PR5-IN-1 |
|
|
|
|
|
|
|
|
|
99.58% |
| SACLAC |
|
|
|
|
|
|
|
|
|
99.70% |
| SAR247799 |
|
|
|
|
|
|
|
|
|
99.38% |
| SEW2871 |
|
|
|
|
|
|
|
|
|
99.88% |
| Siponimod hemifumarate |
|
|
|
|
|
|
|
|
|
99.64% |
| Siponimod-d11 |
|
|
|
|
|
|
|
|
|
|
| SLB1122168 |
|
|
|
|
|
|
|
|
|
|
| SLB1122168 formic |
|
|
|
|
|
|
|
|
|
99.91% |
| SLB1122168 free base |
|
|
|
|
|
|
|
|
|
|
| SLF1081851 |
|
|
|
|
|
|
|
|
|
98.02% |
| SLF1081851 hydrochloride |
|
|
|
|
|
|
|
|
|
|
| SLF1081851 TFA |
|
|
|
|
|
|
|
|
|
|
| SLF80821178 |
|
|
|
|
|
|
|
|
|
99.70% |
| SLF80821178 hydrochloride |
|
|
|
|
|
|
|
|
|
|
| Sonepcizumab |
|
|
|
|
|
|
|
|
|
95.00% |
| Sphingomab |
|
|
|
|
|
|
|
|
|
97.91% |
| SPL-IN-1 |
|
|
|
|
|
|
|
|
|
|
| Spns2-IN-1 |
|
|
|
|
|
|
|
|
|
|
| Spns2-IN-2 |
|
|
|
|
|
|
|
|
|
|
| Spns2-IN-3 |
|
|
|
|
|
|
|
|
|
|
| Sumonerimod hemicalcium |
|
|
|
|
|
|
|
|
|
|
| TAK-615 |
|
|
|
|
|
|
|
|
|
98.07% |
| Tamuzimod |
|
|
|
|
|
|
|
|
|
|
| TASP0277308 |
|
|
|
|
|
|
|
|
|
|
| TC LPA5 4 |
|
|
|
|
|
|
|
|
|
99.69% |
| TC LPA5 4 (Standard) |
|
|
|
|
|
|
|
|
|
|
| TC-SP 14 |
|
|
|
|
|
|
|
|
|
|
| TRV045 |
|
|
|
|
|
|
|
|
|
98.15% |
| TY-52156 |
|
|
|
|
|
|
|
|
|
99.25% |
| TYY-31 |
|
|
|
|
|
|
|
|
|
|
| UCM-05194 ammonium |
|
|
|
|
|
|
|
|
|
|
| Udifitimod |
|
|
|
|
|
|
|
|
|
|
| Vibozilimod |
|
|
|
|
|
|
|
|
|
99.52% |
| VPC 01091 |
|
|
|
|
|
|
|
|
|
|
| VPC 23019 |
|
|
|
|
|
|
|
|
|
99.20% |
| VPC 23153 |
|
|
|
|
|
|
|
|
|
|
| VPC12249 |
|
|
|
|
|
|
|
|
|
|
| W123 |
|
|
|
|
|
|
|
|
|
|
| W140 hydrobromide |
|
|
|
|
|
|
|
|
|
|
| W146 |
|
|
|
|
|
|
|
|
|
99.83% |
| W146 TFA |
|
|
|
|
|
|
|
|
|
98.22% |
| XAX-162 |
|
|
|
|
|
|
|
|
|
|
| XL541 |
|
|
|
|
|
|
|
|
|
|
| Zectivimod |
|
|
|
|
|
|
|
|
|
99.35% |
| Sodium glycocholate hydrate, 98% |
|
|
|
|
|
|
|
|
|
99.91% |
| High density lipoprotein (human) |
|
|
|
|
|
|
|
|
|
|
| Ozanimod |
|
|
|
|
|
|
|
|
|
99.98% |
| Ozanimod-d6 |
|
|
|
|
|
|
|
|
|
|
| Poloxamer 407 (F127) |
|
|
|
|
|
|
|
|
|
|
| Glycocholic acid-d5 |
|
|
|
|
|
|
|
|
|
99.9% |
| Fingolimod hydrochloride |
|
|
|
|
|
|
|
|
|
99.94% |
| Myristoyl pentapeptide-17 |
|
|
|
|
|
|
|
|
|
|
| Fingolimod-d4 |
|
|
|
|
|
|
|
|
|
99.11% |
| Fingolimod-d4 hydrochloride |
|
|
|
|
|
|
|
|
|
99.0% |
| Fingolimod |
|
|
|
|
|
|
|
|
|
99.97% |
| Siponimod |
|
|
|
|
|
|
|
|
|
99.95% |
| Sphingosine-1-phosphate-d7 |
|
|
|
|
|
|
|
|
|
99.9% |
| Sphingosine-1-phosphate |
|
|
|
|
|
|
|
|
|
99.94% |